Taysha Gene Therapies announcement


Exciting news for Rett Families everywhere.

Taysha Gene Therapies have announced today that the Independent Data Monitoring Committee (IDMC) recommended the continuation of the REVEAL Phase 1/2 trial and that dosing of the second patient in the first cohort can proceed.

The decision follows a pre-specified IDMC review of initial clinical data from the first patient dosed with TSHA-102 following the 42-day evaluation period.

“This recommendation was based on the analysis of initial clinical data from the first adult patient with Rett syndrome to receive TSHA-102. A second patient is expected to be dosed in the third quarter of this year.

We are highly encouraged by the initial clinical observations, which support the transformative potential of TSHA-102 and mark important progress in our efforts to bring a gene therapy to patients and families living with Rett syndrome. We look forward to providing an initial clinical update on the first patient at our second quarter corporate update conference call in mid-August.”

Sukumar Nagendran, M.D., President and Head of R&D of Taysha

We look forward to further announcements from Taysha in the coming months.

You can read Taysha’s press release here

You also download a letter to the Rett community from Taysha here